Clinical trials: Stage II Breast Carcinoma
Female Breast Cancer
Estrogen for Triple Negative Breast Cancer
The purpose of this study is to determine the effectiveness of Estradiol treatment for advanced breast cancer that is hormone receptor negative and Her2/neu negative.
- Trial name
- NCT01083641
- Testing
- Estradiol
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Wisconsin, Madison
Breast Cancer
Everolimus in Treating Patients WIth Recurrent or Metastatic Breast Cancer
RATIONALE: Everolimus may stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This randomized phase II trial is studying two different schedules of everolimus to see how well they work in treating…
- Trial name
- NCT00255788
- Testing
- everolimus
- Where
- 5 sites in Canada
- Volunteers
- 49 people
- Sponsor
- NCIC Clinical Trials Group
HER2-negative Breast Cancer
Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases
This is a prospective, open-label, phase II platform trial. The purpose of this study is to test the safety and effectiveness of multi-mode thermal therapy combined with immunotherapy in patients with HER2-negative breast cancer…
- Trial name
- NCT07466927
- Testing
- SHR-A1811, SKB264, Pembrolizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Metastatic Breast Cancer
Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer
Phase I part: to determine the recommended dose, and observe the preliminary response and safety profile of the combination of oral lapatinib with vinorelbine in patients with ErbB2 positive metastatic breast cancer.
- Trial name
- NCT00912275
- Testing
- lapatinib plus oral vinorelbine
- Where
- Taiwan
- Volunteers
- 46 people
- Sponsor
- National Taiwan University Hospital
Stage 0 Breast Cancer, Stage I Breast Cancer
Web-Based Decision Aid in Improving Informed Decisions in Patients With Stage 0-IIIA Breast Cancer Considering Contralateral Prophylactic Mastectomy
This pilot randomized clinical trial studies how well a web-based decision aid works in improving informed decisions in patients with stage 0-IIIA breast cancer considering contralateral prophylactic mastectomy (CPM).
- Conditions
- Stage 0 Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer
- Trial name
- NCT03061175
- Testing
- Internet-Based Intervention, Survey Administration
- Where
- 3 sites in United States
- Volunteers
- 94 people
- Sponsor
- Rutgers, The State University of New Jersey
Triple-negative Breast Cancer
Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer
Evaluate if the two carboplatin containing chemotherapy regimens will reduce the growth of breast cancer cells in women with Stage I, II, or III triple negative breast cancer.
- Trial name
- NeoSTOP (NCT02413320)
- Testing
- Paclitaxel, Carboplatin, Doxorubicin
- Where
- 9 sites in United States
- Volunteers
- 101 people
- Sponsor
- Priyanka Sharma
Breast Cancer
Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.
The study is designed to explore the clinical benefit following treatment with tucidinosta in combination with metronomic capecitabine and endocrine therapy in patients with hormone receptor-positive, Her2-negative advanced…
- Trial name
- NCT05411380
- Testing
- Tucidinostat, Capecitabine, Endocrine Therapy
- Where
- China
- Volunteers
- 73 people
- Sponsor
- wang shusen
Breast Cancer Stages I, Breast Cancer Stages II
Evaluation of the Efficacy of Biobran (Rice Bran Arabinoxylan) in Supporting Breast Cancer Chemotherapy
This study aims to evaluate the potential supportive effects of rice bran arabinoxylan compound (Biobran) in patients with breast cancer receiving paclitaxel and doxorubicin chemotherapy.
- Conditions
- Breast Cancer Stages I, Breast Cancer Stages II, Breast Cancer Stage III
- Trial name
- NCT07503496
- Testing
- Biobran supplementation
- Where
- 2 sites in Taiwan
- Volunteers
- 96 people
- Sponsor
- China Medical University Hospital
Breast Cancer
Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002679
- Testing
- filgrastim, cyclophosphamide, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Yale University
BREAST CANCER
Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer
The investigators want to know if combining Arimidex and Faslodex with Iressa will be an effective treatment for breast cancer. They also want to know, using special tests on the tumor, the changes that occur with the treatment…
- Trial name
- NCT00206414
- Testing
- Iressa Day 1 given with Arimidex and Faslodex, Iressa Day 21 given with Arimidex and Faslodex
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Baylor Breast Care Center
Breast Cancer
Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole +/- goserelin (the latter for pre-menopausal women only) may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT01013506
- Testing
- IGF-1R inhibitor OSI-906, erlotinib hydrochloride, goserelin
- Sponsor
- Vanderbilt-Ingram Cancer Center
Stage IV Breast Cancer, Recurrent Breast Cancer
Antineoplaston Therapy in Treating Women With Advanced Breast Cancer
RATIONALE: Antineoplastons are naturally-occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells.
- Trial name
- NCT00003455
- Testing
- antineoplaston A10, antineoplaston AS2-1, alternative product therapy
- Where
- United States
- Sponsor
- Burzynski Research Institute
Breast Cancer
Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00080626
- Testing
- pegfilgrastim, docetaxel, conventional surgery
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer, Metastasis, Neoplasm
Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer (MBC)
The primary objective of this study is to evaluate the efficacy and tolerability of sequential use of vinorelbine and capecitabine as first line therapy in patients with MBC.
- Trial name
- NCT00629148
- Testing
- Vinorelbine and Capecitabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Breast Cancer
A Clinical Trial Evaluating the Safety and Clinical Activity of Radioiodide (131I-) as a Novel Targeted Therapy for Metastatic Breast Cancer That Overexpresses Functional Na/I Symporter
The purpose of this phase I/II study is to evaluate the safety and clinical activity of Radioiodide (131I-) as a novel targeted therapy for metastatic breast cancer that overexpresses functional Na/I symporter.
- Trial name
- NCT02988648
- Testing
- Radioiodide (131I-)
- Where
- United States
- Sponsor
- Yale University
TNBC, Brain Metastasis
SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases
This is a phaseⅡ, single-arm study evaluating the efficacy and safety of SHR-A1921 Combined with Bevacizumab in Triple-negative Breast Cancer with Brain Metastases
- Trial name
- NCT06210438
- Testing
- SHR-A1921 + Bevacizumab
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Fudan University
Metastatic Breast Cancer
A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
This is a multicenter, single-arm phase II clinical trial to evaluate the efficacy and safety of RC48 in metastatic human epidermal growth factor receptor 2 (HER2) expressing breast cancer with abnormal activation of PAM pathway.
- Trial name
- NCT05331326
- Testing
- RC48-ADC
- Where
- 3 sites in China
- Volunteers
- 64 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Cancer
Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus Aromatase Inhibitor in Metastatic HER2+/HR+ Breast Cancer
Antibody-dependent cell-mediated cytotoxicity (ADCC) is one of the important mechanisms for suppressing tumors of Trastuzumab. Pre-clinical data suggest that the ADCC effect of Inetetamab, an anti-HER2 monoclonal antibody with a…
- Trial name
- Increase (NCT04941885)
- Testing
- Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- 15-95 (NCT00002784)
- Testing
- filgrastim, CMF regimen, cyclophosphamide
- Where
- 11 sites in Australia, Switzerland
- Volunteers
- 344 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer, Lung Cancer
A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)
Patients suffering from histologically or cytologically confirmed stage IV lung or breast cancer with progressive or recurrent brain metastases after prior external beam radiotherapy will receive treatment with cabazitaxel until…
- Conditions
- Breast Cancer, Lung Cancer, Recurrent Brain Metastases, Progressive Brain Metastases
- Trial name
- CaBaMet (NCT02166658)
- Testing
- Cabazitaxel
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- AIO-Studien-gGmbH